Five patients with PIK3CA mutant tumors were treated with the THP regimen, and four of them (80%) achieved pCR: three with a hormone-receptor-negative tumor, and one with a hormone-receptor-positive tumor. The gene discussed is PIK3CA; the disease is neoplasm.